Interestingly, blocking TNFR1 signaling with ATROSAB prevented membrane-bound TNF from activating neuroprotective signaling via TNFR2, further explaining the ineffectiveness of anti-TNF as therapeutic in neurodegenerative diseases. This evidence concerns the gene TNFRSF1A and neurodegenerative disease.